WO2018057506A1 - Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy - Google Patents

Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy Download PDF

Info

Publication number
WO2018057506A1
WO2018057506A1 PCT/US2017/052246 US2017052246W WO2018057506A1 WO 2018057506 A1 WO2018057506 A1 WO 2018057506A1 US 2017052246 W US2017052246 W US 2017052246W WO 2018057506 A1 WO2018057506 A1 WO 2018057506A1
Authority
WO
WIPO (PCT)
Prior art keywords
ifng
cxcl9
lag3
cancer
antibody
Prior art date
Application number
PCT/US2017/052246
Other languages
English (en)
French (fr)
Inventor
Brandon W. Higgs
Chris Morehouse
Philip Brohawn
Katie Streicher
Koustubh Ranade
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Priority to EP17853747.8A priority Critical patent/EP3515456A4/en
Priority to CN201780070587.5A priority patent/CN109963572A/zh
Priority to JP2019515363A priority patent/JP2019529437A/ja
Publication of WO2018057506A1 publication Critical patent/WO2018057506A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
PCT/US2017/052246 2016-09-20 2017-09-19 Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy WO2018057506A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP17853747.8A EP3515456A4 (en) 2016-09-20 2017-09-19 COMPOSITIONS AND METHODS FOR CHARACTERIZING THE REACTIVITY OF SOLID TUMORS TO ANTI-PD-L1 ANTIBODY MONOTHERAPY
CN201780070587.5A CN109963572A (zh) 2016-09-20 2017-09-19 用于表征实体瘤对抗pd-l1抗体单一疗法的反应性的组合物和方法
JP2019515363A JP2019529437A (ja) 2016-09-20 2017-09-19 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662397062P 2016-09-20 2016-09-20
US62/397,062 2016-09-20

Publications (1)

Publication Number Publication Date
WO2018057506A1 true WO2018057506A1 (en) 2018-03-29

Family

ID=61691137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/052246 WO2018057506A1 (en) 2016-09-20 2017-09-19 Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy

Country Status (4)

Country Link
EP (1) EP3515456A4 (zh)
JP (1) JP2019529437A (zh)
CN (1) CN109963572A (zh)
WO (1) WO2018057506A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
WO2023064784A1 (en) * 2021-10-12 2023-04-20 Foundation Medicine, Inc. Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
EP4010022A4 (en) * 2019-08-09 2024-01-17 The Regents Of Univ Of California COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF BLADDER CANCER

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151006A2 (en) * 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2016034718A1 (en) * 2014-09-05 2016-03-10 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095363A1 (es) * 2013-03-15 2015-10-14 Genentech Inc Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151006A2 (en) * 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2016034718A1 (en) * 2014-09-05 2016-03-10 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3515456A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
US11807686B2 (en) 2017-05-30 2023-11-07 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
EP4010022A4 (en) * 2019-08-09 2024-01-17 The Regents Of Univ Of California COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF BLADDER CANCER
WO2023064784A1 (en) * 2021-10-12 2023-04-20 Foundation Medicine, Inc. Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy

Also Published As

Publication number Publication date
EP3515456A4 (en) 2020-06-17
EP3515456A1 (en) 2019-07-31
CN109963572A (zh) 2019-07-02
JP2019529437A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
US20230375555A1 (en) Markers selectively deregulated in tumor-infiltrating regulatory t cells
EP3515456A1 (en) Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy
US10927410B2 (en) Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
US20180079814A1 (en) Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
KR20210088559A (ko) 암 요법에 사용하기 위한 활성화 항원 수용체 (aCAR)/저해성 키메라 항원 수용체 (iCAR) 쌍의 식별 방법
US20170240632A1 (en) Compositions and methods for identifying and treating cachexia or pre-cachexia
US20170275347A1 (en) Methods for identifying patients responsive to anti-pd-l1 antibody therapy
WO2016030455A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
JP6941561B2 (ja) 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
WO2018183817A2 (en) Tumor burden as measured by cell free dna
CN110945030A (zh) 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法
KR20220022050A (ko) 지속적인 임상 이익을 위한 암 바이오마커
KR20220031069A (ko) 항-종양 치료의 효과를 진단하기 위한 방법
US20210071258A1 (en) Gene expression and assessment of risk of developing toxicity following cell therapy
WO2019164870A1 (en) Expression of signature mrnas for identifying patients responsive to anti-pd-l1 antibody therapy
WO2022120179A1 (en) Multi-tumor gene signatures and uses thereof
EP3464614B1 (en) Method for the prognosis of multiple myeloma
GB2535256A (en) Combination therapy for PD-L1 negative tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17853747

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019515363

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017853747

Country of ref document: EP

Effective date: 20190423